ATS 2024 Final Program

Click on the session title to view the speakers

68

SUNDAY • MAYs 19

P613 Coronary Microvascular Dysfunction in Group 2 Pulmonary Hypertension P614 Guideline-based Pre-test Probability Strategy to Detect Patients With Left Heart Disease-associated Pulmonary Hypertension P615 Nocturnal Hypoxemia and Sleep-Disordered Breathing in Postcapillary Pulmonary Hypertension P616 “Bridging the Gap: How SGLT2 Inhibitors Are Transforming HFpEF Outcomes” a Systemic Review and Meta Analysis P617 Differential Blood Pressure and Heart Rate Response to 6-minute Walk Testing in Patients With Group 1 Vs. Group 2 Pulmonary Hypertension P618 Phosphodiaterase-5 Inhibitors in Pulmonary Hypertension From Left Heart Disease: A Systematic Review A58 EXPANDING OUR RE(PERT)OIRES IN SAN DIEGO: NOVEL CLINICAL DISCOVERIES IN PULMONARY EMBOLISM 9:15 a.m. - 4:15 p.m. San Diego Convention Center Area F (Hall A-B2, Ground Level) Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P620 Thrombectomy Vs Thrombolysis for the Management of Acute Pulmonary Embolism: A Propensity Matched National Analysis P621 The Safety of Transcatheter Interventions for Acute Pulmonary Embolism in End Stage Renal Disease: A Propensity Matched National Study P622 Safety of Transcatheter Interventions for Acute Pulmonary Embolism in Liver Cirrhosis: A Propensity Matched National Study P623 Bidirectional Two-sample Mendelian Randomization Study Identifies Renal Function Is Causally Associated With Pulmonary Embolism in East Asian Population CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

P602 Quantitative CT Measures of the Pulmonary Vasculature to Distinguish Between Pulmonary Hypertension Groups P603 Comparison of Echocardiogram-derived Markers of Pulmonary Hypertension Before and After COVID-19 Infection P604 Rapid Inpatient Parenteral to Oral Prostacyclin Transition Therapy in High Risk PAH Patients With Relative Contraindications to Outpatient Intravenous Therapy: A Retrospective Case Series P605 Interobserver Reliability and Accuracy of the Visual Assessment of Interventricular Septal Flattening in Pulmonary Hypertension P606 Efficacy and Safety of Tadalafil and Sildenafil in Pulmonary Arterial Hypertension: Results of a Systematic Literature Review P607 Finding PH -developing a Referral System for Pulmonary Hypertension Evaluation Based on Echocardiographic Findings P608 Therapeutic Regimen Practices for Pulmonary Arterial Hypertension (PAH) Patients at a Tertiary Academic PAH Center in South Texas P609 Insulin Resistance as a Marker of Pulmonary Arterial Hypertension P610 The Utility and Pitfalls of Cardiopulmonary Exercise Testing Diagnosis of Pulmonary Hypertension in the Long COVID Era P611 Cardiopulmonary Exercise Testing Evaluation of Long COVID

CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

A57 SOCAL GROUPIES IN PH: GROUP 2 PH AND LEFT HEART DISEASE 9:15 a.m. - 4:15 p.m. Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees San Diego Convention Center Area F (Hall A-B2, Ground Level)

ATS 2024 Conference Program • San Diego, CA